Raise your investment strategy:
- Take advantage of Premium Tipranks at 55% reduction! Unlock powerful investment tools, advanced data and expert analyst information to help you invest with confidence.
An announcement of the Sucilex Holding Company ((SCLX)) is now available.
September 23, 2025, SICIX HOLDING COMPANY announced the signing of a securities purchase agreement with Biconomy PTE.LTD to exchange 200 million dollars in ordinary shares in its subsidiary, Semnur Pharmaceuticals, for Bitcoin. This transaction, which closed its doors on September 25, 2025, marks Sucilex’s strategic entry into the cryptocurrency market, with bicomy providing professional services for cryptographic market strategies. This decision should have an impact on Sucilex’s operations by diversifying its financial strategies and potentially improving its market positioning.
The most recent analyst note on (SCLX) is a purchase with a price target of $ 770.00. To see the complete list of analysts forecasts on the actions of Sucilex Holding Company, see the SCLX Actions forecasting page.
Learn more about Sucilex Holding Company
SCILEX HOLDING COMPANY is an innovative company generating income focused on the acquisition, development and marketing of non -opioid pain management products for the treatment of acute and chronic pain, as well as neurodegenerative and cardiometabolical diseases. The company targets indications with unatstated high needs and large market opportunities, offering non -opioid therapies to improve results for patients. SCILEX’s commercial products include ZTLIDO®, ELYXYB® and GLOPERBA®, and it also develops candidate products like SP-102, SP-103 and SP-104.
Average trading volume: 233 494
Technical feeling signal: Buy
Current stock market cup: $ 198.9 million
For detailed information on the SCLX stock, go to Tipranks stock analysis page.
Warning and disclosure
